Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
NCT ID: NCT00707876
Last Updated: 2019-04-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
108 participants
INTERVENTIONAL
2008-09-30
2019-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic Performance of a Novel Ferumoxytol-Enhanced Magnetic Resonance Angiography/ Venography on Panvascular Disease
NCT06136806
Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease
NCT00296855
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries
NCT00309075
MRI Guided Management of Occlusive Peripheral Arterial Disease
NCT06782100
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
NCT07348640
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Dose 1 versus non-contrast MRA
ferumoxytol
Dose 1 versus non-contrast MRA
2
Dose 2 versus non-contrast MRA
ferumoxytol
Dose 2 versus non-contrast MRA
3
Dose 3 versus non-contrast MRA
ferumoxytol
Dose 3 versus non-contrast MRA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ferumoxytol
Dose 1 versus non-contrast MRA
ferumoxytol
Dose 2 versus non-contrast MRA
ferumoxytol
Dose 3 versus non-contrast MRA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Scheduled for DSA
Exclusion Criteria
* Laboratory evidence of iron overload, liver disease, pregnancy
* History of allergy to or recent exposure to radiocontrast, gadolinium chelates, or intravenous iron therapy
* Clinical concerns about co-morbidities, subject suitability
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AMAG Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Strauss, MD
Role: STUDY_DIRECTOR
AMAG Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lexington, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FER-PAD-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.